Levetiracetam Eignapharma (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This reduces excessive neuronal firing and stabilizes brain activity, thereby decreasing the likelihood of seizure initiation and spread.

The appropriate dose of Levetiracetam Eignapharma is individualized and set by the prescribing clinician based on the patient’s age, weight, renal function, seizure type, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for levetiracetam in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where applicable), and import documentation.

Levetiracetam offers a favorable safety profile and minimal drug‑enzyme interactions compared with many older antiepileptics such as carbamazepine or phenytoin. It is often chosen for patients who require rapid intravenous control of seizures or who have experienced adverse effects with alternative agents.

Levetiracetam injection should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if the solution appears discolored or contains particles.

The medication is given as an intravenous injection by a qualified healthcare professional. The infusion rate and total daily dose are determined by the prescriber, taking into account the patient’s clinical condition and renal function.

Serious adverse events include severe allergic reactions (anaphylaxis, angioedema), life‑threatening skin conditions such as Stevens‑Johnson syndrome, blood disorders like neutropenia or thrombocytopenia, and emergence of suicidal thoughts or behavior. Prompt medical attention is required if any of these occur.

Patients with a known hypersensitivity to levetiracetam or any component of the formulation should avoid the drug. Those with severe renal impairment must have dose adjustments; otherwise, use is contraindicated. Caution is also advised in individuals with a history of psychiatric disorders or suicidal ideation.